Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Njoku, C. J. Articles by Stich, R. W. Search for Related Content PubMed PubMed Citation Articles by Njoku, C. J. Articles by Stich, R. W.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, May 2002, p. 605-610, Vol. 9, No. 3
1071-412X/02/$04.00+0     DOI: 10.1128/CDLI.9.3.605-610.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Reduced Levels of Nitric Oxide Metabolites in Cerebrospinal Fluid Are Associated with Equine Protozoal Myeloencephalitis

Chinedu J. Njoku,¹ William J. A. Saville,¹ Stephen M. Reed,² Michael J. Oglesbee,³ Päivi J. Rajala-Schultz,¹ and Roger W. Stich^1*

Department of Veterinary Preventive Medicine,¹ Department of Veterinary Clinical Sciences,² Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio 43210³

Received 23 July 2001/ Returned for modification 3 October 2001/ Accepted 7 January 2002

Top Abstract Introduction Materials and Methods Results Discussion References

 
Equine protozoal myeloencephalitis (EPM) is a disease of horses that is primarily associated with infection with the apicomplexan Sarcocystis neurona. Infection with this parasite alone is not sufficient to induce the disease, and the mechanism of neuropathogenesis associated with EPM has not been reported. Nitric oxide (NO) functions as a neurotransmitter, a vasodilator, and an immune effector and is produced in response to several parasitic protozoa. The purpose of this work was to determine if the concentration of NO metabolites (NO_x^-) in the cerebrospinal fluid (CSF) is correlated with the development of EPM. CSF NO_x^- levels were measured before and after transport-stressed, acclimated, or dexamethasone-treated horses (n = 3 per group) were experimentally infected with S. neurona sporocysts. CSF NO_x^- levels were also compared between horses that were diagnosed with EPM after natural infection with S. neurona and horses that did not have clinical signs of disease or that showed no evidence of infection with the parasite (n = 105). Among the experimentally infected animals, the mean CSF NO_x^- levels of the transport-stressed group, which had the most severe clinical signs, was reduced after infection, while these values were found to increase after infection in the remaining groups that had less severe signs of EPM. Under natural conditions, horses with EPM (n = 65) had a lower mean CSF NO_x^- concentration than clinically normal horses with antibodies (Abs) against S. neurona (n = 15) in CSF, and horses that developed ataxia (n = 81) had a significantly lower mean CSF NO_x^- concentration than horses that did not have neurologic signs (n = 24). In conclusion, lower CSF NO_x^- levels were associated with clinical EPM, suggesting that measurement of CSF NO_x^- levels could improve the accuracy of diagnostic tests that are based upon detection of S. neurona-specific Abs in CSF alone and that reduced NO levels could be causatively related to the development of EPM.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Equine protozoal myeloencephalitis (EPM) is a disease of horses that is primarily attributed to the onset of ataxia after infection with the protozoan parasite Sarcocystis neurona (8). The disease affects the central nervous system (CNS); and clinical signs may be representative of those affected by any area of the CNS including stumbling, depression, ataxia, spasticity, weakness, and cranial nerve deficits that are sometimes accompanied by associated muscle atrophy (9, 12, 21). Progression of clinical signs is variable. EPM is reportedly the most prevalent cause of neurologic disease of horses in the Americas, and the estimated annual cost of diagnosis and treatment of EPM in the United States has been estimated at $110 million (9). Over 30% of the horses in some parts of the United States have antibodies (Abs) to S. neurona (4, 5, 29). However, it has been estimated that 1% of exposed horses develop EPM (i.e., ataxia in association with S. neurona-specific Abs in the cerebrospinal fluid [CSF]), indicating that additional factors also contribute to the onset of this disease (9). An accurate experimental model for EPM has not been developed, underscoring the complex etiology of this disease and the need for further understanding of the pathogenic mechanisms responsible for its onset. Investigation of aspects of EPM other than the infection alone will help elucidate its poorly understood pathogenesis.

Previously, we reported on the association between stress and EPM and how this has been used to develop an experimental equine model for EPM (31). Three groups of horses were experimentally infected with S. neurona sporocysts from feral opossums either immediately upon arrival as a test of the effect of transport stress, after a 2-week acclimation period, or after dexamethasone treatment as a test of the effect of immunosuppression. All of these horses seroconverted and developed anti-S. neurona Ab titers in their CSF after sporocyst inoculation. Interestingly, the transport-stressed group had horses with the highest clinical scores but the fewest animals with histopathologic lesions in the CNS, while the dexamethasone-treated group had horses with lower clinical scores but a larger number of individual horses with lesions in the CNS (31). These results indicate that the severity of the clinical signs due to EPM was not associated with the severity of lesions in the CNS but, rather, was due at least in part to a factor other than parasite load.

Nitric oxide (NO) is a versatile molecule that can function as a neurotransmitter, a vasodilator, and an immune effector, indicating that EPM could be associated with altered levels of NO production in association with S. neurona infection of the CNS. All three NO synthase (NOS) isoforms, inducible NOS (iNOS), endothelial NOS, and neuronal NOS, have been reported in the mammalian CNS (7). Evidence of either increased or reduced levels of NO production has been reported in association with several neurologic disorders (1, 16, 19, 26), and NO production has also been demonstrated in the presence of gamma interferon (IFN-) and parasitic protozoa (14, 20, 23, 27, 33, 34). Increased iNOS activity has also been reported in the CNS and CSF of rabbits with experimental bacterial meningitis, and mercaptoethylguanidine, a peroxynitrite scavenger and iNOS inhibitor, was found to reduce the pathogenesis of this disease without affecting the bacterial infection level (16). The purpose of this study was to investigate the association between NO production and the onset of EPM.

The approach to this investigation was to compare the NO metabolites nitrite (NO₂^-) and nitrate (NO₃^-), collectively referred to as NO_x^-, in the CSF of horses with experimental or naturally occurring cases of EPM. CSF was collected from experimental horses before and after infection with S. neurona sporocysts collected from feral opossums. Challenge groups included horses subjected to transport-related stress, acclimated horses, or horses treated with dexamethasone prior to infection. NO_x^- levels were also measured in the CSF collected from horses admitted to The Ohio State University Veterinary Teaching Hospital (OSU VTH) for clinical neurologic examination. Lower CSF NO_x^- levels were associated with the onset of clinical EPM, suggesting novel approaches to the diagnosis and control of this disease.

Top Abstract Introduction Materials and Methods Results Discussion References

 
Horses. For experimental infection, nine horses that were seronegative for S. neurona were randomly assigned to three groups (a transport-stressed group, an acclimated group, and a group treated with dexamethosone after acclimation) prior to inoculation with S. neurona sporocysts from feral opossums, which is reported elsewhere (31). Briefly, these horses were shipped to the site of study and subjected to neurologic examinations by a masked observer on the day of arrival, at the time of inoculation, and biweekly thereafter. Transport-stressed horses were inoculated with S. neurona within a few hours upon arrival (day 0). Acclimated horses were inoculated with S. neurona 14 days after arrival. Steroid-treated horses received 0.5 mg of dexamethasone per kg of body weight (intramuscularly) on days 12 to 14 prior to inoculation with S. neurona on day 14, and semiweekly dexamethasone doses (0.2 mg/kg) were continued for the remainder of the study. CSF samples were collected on the days of infection and necropsy, as described previously (13).

For the groups in the natural exposure study, CSF samples were collected only once from each of the equine patients admitted to the OSU VTH from December 1997 through June 1998 for neurologic examination. Each horse was subjected to two independent neurologic examinations by different clinical observers prior to collection of CSF. Other potential causes of neurologic disease in horses include arboviral encephalitogens, equine herpesvirus, aberrant metazoan parasite migration, spinal and cerebral abscesses, and cervical vertebral malformation (9, 22). The differential diagnosis of EPM from other diseases that result in similar clinical signs requires a detailed clinical examination, in addition to appropriate laboratory tests. The laboratory tests used in this study were performed at the discretion of the clinical examiners, and in part due to the prevalence of EPM and common vaccination procedures for other pathogens that affect the CNS, S. neurona was determined to be the only infectious agent responsible for neurologic disease in these horses. Horses with neurologic disease in the absence of anti-S. neurona Abs in their CSF were diagnosed as suffering from noninfectious neurologic disorders. Naturally exposed and unexposed horses were divided into four groups on the basis of the display of ataxia and the presence of anti-S. neurona Abs in the CSF: (i) those that were ataxic (A+), a clinical sign of EPM, and that had anti-S. neurona Abs in their CSF (C+), (ii) those that were not ataxic (A-) and that did not have anti-S. neurona Abs in their CSF (C-), (iii) those that were A+ but C-, and (iv) those that were A- but C+.

Examiners in both the experimental and the natural infection studies used the same grading system to evaluate the levels of ataxia of experimentally and naturally exposed horses. These scores ranged from 0 to 5 relative to worsening levels of clinical signs. Horses with a score of 0 had a normal gait with no deficits. A score of 1 indicated deficits that were barely perceptible and that worsened with head elevation. A score of 2 was given to horses with notable deficits at a walk. Horses that had deficits at rest or walking or that nearly fell with head elevation received a score of 3. Horses that fell or nearly fell without head elevation received a score of 4. Finally, recumbent patients received a score of 5.

Assay of CSF NO_x^- levels. Each CSF sample was placed in quadruplicate wells (50 µl/well) of a 96-well, flat-bottom microtiter plate (Linbro; Flow Laboratories, Inc., McLean, Va.) and treated with 4.5 x 10^-4 units of NO₃^- reductase per µl in the presence of 62.5 µM NADPH (Roche Diagnostics Corporation, Indianapolis, Ind.) and 140 µM flavin adenine dinucleotide (Sigma, St. Louis, Mo.) in a total volume of 80 µl. The reaction mixture was incubated for 4 h at room temperature in the dark prior to assay with the Griess reagent, which consisted of addition of equal volumes of 1% sulfanilamide (in 5% phosphoric acid) and 0.1% N-1-naphthylethylenediamine dihydrochloride (Promega, Madison, Wis.), mixing of the samples via pipetting, and measurement of the optical density at 540 nm with a microtiter plate reader (Titertek Multiskan; Flow Laboratories, Inc.) (34). A standard curve for KNO₃ at concentrations from 0 to 80 µM was used to calculate NO_x^- concentrations.

Statistical analysis. Calculation of standard descriptive statistics was performed with a routinely used statistical program (SAS version 8.01; SAS Institute Inc., Cary, N.C.). Descriptive statistics for continuous variables included means and standard errors. Frequency distributions were calculated for categorical variables, and graphs were generated where appropriate. For the experimentally infected horses, the means between two groups were compared, with significance determined at an alpha level of 0.05. A mixed model (Proc Mixed, SAS version 8.01) was used when more than two groups of horses admitted to the OSU VTH (n = 4) were compared and the outcome of interest was NO_x^- values for all horses. The least-squares means for each of the four categories were calculated, and the Tukey-Kramer procedure was used for multiple comparisons between the groups. The chi-square test was used to compare the numbers of ataxic horses with or without anti- S. neurona Abs in their CSF. An alpha level of 0.05 was used for determination of significant differences between groups.

Among horses that tested positive by the combination of the assay for Abs in CSF and the assay for the NO_x^- concentration in CSF, animals with true-positive (TP) results for EPM were defined as those that had anti- S. neurona Abs in their CSF, as determined by Western analysis (Equine Biodiagnostic Inc., Lexington, Ky.), and that displayed an ataxia score of 1, as determined by the clinical examiners. Nonataxic horses in this group were false positive (FP). Among horses that tested negative by the combination of the assay for Abs in CSF and the assay for the NO_x^- concentration in CSF, those that lacked anti-S. neurona Abs in their CSF or that had an ataxia score of 0 were considered to have true-negative (TN) results for EPM, while those that were ataxic and that had anti-S. neurona Abs in their CSF were considered to have false-negative (FN) results. The sensitivity was defined as TP/(TP + FN), the specificity was defined as TN/(TN + FP), the positive predictive value was defined as TP/(TP + FP), and the negative predictive value was defined as TN/(TN + FN) (6).

Top Abstract Introduction Materials and Methods Results Discussion References

 
CSF NO_x^- levels in experimentally infected horses. NO_x^- levels were measured in CSF collected prior to and following experimental infection of horses to determine if NO production could explain the differences in clinical EPM observed between stressed, acclimated, and dexamethasone-treated horses (31). No difference in CSF NO_x^- levels was observed among the acclimated, dexamethasone-treated, or transport-stressed groups before they were exposed to S. neurona; but NO_x^- levels were different (P < 0.05) among each of these groups after infection (Fig. 1). CSF NO_x^- concentrations increased for the acclimated and dexamethasone-treated groups after exposure to S. neurona. Conversely, the CSF NO_x^- concentration of the transport-stressed animals, which had the highest ataxia scores, decreased after the onset of EPM.

View larger version (26K): [in this window] [in a new window]

FIG. 1. CSF NOx- levels in horses experimentally infected with S. neurona. Nine horses were divided into three groups that were subjected to transport stress, allowed to acclimate, or treated with dexamethasone (Dexameth.) prior to inoculation with sporocysts. CSF samples were collected before (open bars) and after (hatched bars) infection. Mean plus standard error CSF NOx- concentrations for each group, determined from assays of quadruplicate wells for each horse, are presented. Values with different superscripts are statistically different (P < 0.05).

CSF NO_x^- levels in naturally infected horses. The CSF NO_x^- concentrations in experimentally infected horses indicated that lower CSF NO_x^- levels could be associated with EPM, but not all of these samples were collected at the time of peak clinical disease and the small numbers of individuals in these groups made quantitative differences in clinical signs difficult to demonstrate. Thus, 105 CSF samples collected from horses admitted to the OSU VTH were assayed to determine if lower NO_x^- concentrations could be associated with EPM in animals with cases that developed under natural conditions. These animals were arranged into four groups on the basis of the presence (C+) or absence (C-) of anti- S. neurona Abs in CSF in combination with ataxia scores of 0 (normal or A-) or 1 (ataxic or A+). Only those horses that were both C+ and A+ were considered to have clinical EPM.

The C+ A+ group (i.e., horses with EPM) had a lower mean CSF NO_x^- concentration than the C+ A- group by use of the mixed model (P = 0.012), and this difference also approached significance in the multiple pairwise comparison by use of the more conservative Tukey-Kramer adjustment (P = 0.0571) (Fig. 2). The mean CSF NO_x^- level for the C+ A+ group was also lower than that for the C- A- group, but this difference was not significant (P = 0.0920), possibly due to the small number of horses in the latter group (n = 9). No significant difference was observed between the C+ A+ group and the C- A+ group. The A+ horses had a lower mean CSF NO_x^- concentration than A- horses (P = 0.0068), indicating that lower CSF NO_x^- levels could be associated with neurologic disease in general rather than EPM specifically. A total of 80.25% of the A+ horses were also C+, but this value was not significantly different from the 62.5% of A- horses that were also C+ (P = 0.0730). A small inverse trend (r = 0.286) was observed between the degree of ataxia and the concentrations of NO_x^- in the CSF of these horses (Fig. 3). The range of CSF NO_x^- concentrations for each ataxia score also appeared to narrow as the level of ataxia increased.

View larger version (15K): [in this window] [in a new window]

FIG. 2. CSF NOx- levels of horses naturally exposed to S. neurona. CSF samples were assayed from 105 horses admitted to the OSU VTH from December 1997 through June 1998. Results are divided into four groups, based on ataxia scores of 0 (A-) or 1 (A+) and the presence (C+) or absence (C-) of anti- S. neurona Abs in the CSF. C+ A+ horses were considered to have EPM. The numbers of horses in the C+ A+, C- A+, C+ A-, and C- A- groups were 65, 16, 15, and 9, respectively. Least-squares means plus standard errors for each group, determined by assay of quadruplicate wells for each horse, are presented. The asterisk indicates a different value from that for the C+ A+ group, as determined by the mixed procedure described in the text (P < 0.05).

View larger version (12K): [in this window] [in a new window]

FIG. 3. Inverse relationship between the levels of ataxia and CSF NOx- levels. The mean concentration of NOx- in the CSF of equine patients described in Fig. 2 were plotted according to their ataxia scores, and the linear regression was determined with Microsoft Excel software. The numbers of horses in each group with ataxia scores of 0 to 5 were 22, 9, 49, 18, 4, and 3, respectively.

Sensitivity and specificity curves of cutoff values for NO_x^- concentrations in CSF were plotted to evaluate the ability of this assay to differentiate horses with EPM from horses without EPM (Fig. 4). The sensitivity and specificity curves intercepted at approximately 60% with a cutoff value of the CSF NO_x^- concentration of approximately 11 µM when the test for Abs in CSF was used and intercepted at 55% with a cutoff of 10 µM in the absence of a test for Abs in CSF. For the combination of the test for Abs in CSF and a cutoff value of 11 µM for the CSF NO_x^- concentration, the positive predictive value was 0.784 and the negative predictive value was 0.553. The specificities of the test for CSF NO_x^- concentrations in the presence and in the absence of a test for anti-S. neurona Abs in CSF were similar at the lower cutoff values, where the sensitivity was relatively low. However, diagnosis of EPM was more specific in conjunction with the detection of anti-S. neurona Abs in CSF at the intercept of the specificity and sensitivity curves.

View larger version (15K): [in this window] [in a new window]

FIG. 4. Sensitivity and specificity of a test for determination of NOx- levels in CSF for the diagnosis of EPM. Horses that were C+ A+ were defined as having EPM. The mean concentration of NOx- in the CSF of equine patients described in Fig. 2 were used to predict the percent sensitivity and percent specificity of different cutoff values of the concentration of NOx- in CSF for the diagnosis of EPM. The solid line represents the percent sensitivity curve of the test for the concentration of NOx- in CSF. The line composed of small dashes represents the specificity of the test for the concentration of NOx- in CSF. The line composed of large dashes represents the specificity of the test for the concentration of NOx- in CSF in the presence of a test for anti-S. neurona Abs in CSF.

Top Abstract Introduction Materials and Methods Results Discussion References

 
A reduction in CSF NO_x^- levels after experimental exposure to S. neurona was observed for transport-stressed horses, which had the highest ataxia scores, while increased CSF NO_x^- levels were observed for horses in the acclimated and dexamethasone-treated groups. In addition, CSF NO_x^- levels were lower in horses with naturally occurring cases of EPM (i.e., those horses that had S. neurona-specific Abs in their CSF and that were ataxic) than in nonataxic horses that had S. neurona-specific Abs in their CSF. Experimental exposure of horses to S. neurona allowed the use of preinfection CSF from each horse as a negative control, the comparison of different preinfection treatments to invoke EPM, the use of a homogeneous source of hosts and parasite, and the observation of CNS lesions at necropsy. The study with experimentally infected horses was complemented by the natural exposure study that consisted of a much larger, heterogeneous, and outbred population of horses with clinical signs and asymptomatic, unexposed, or naturally exposed horses. The association of lower CSF NO_x^- levels with clinical signs of EPM among horses with experimentally or naturally induced EPM indicated that this observation could be used to develop an experimental model for EPM that resembles the disease that occurs under natural conditions (30, 31).

Our results suggest that there is an increase in the level of NO production in the presence of S. neurona infection when the hosts are not stressed under experimental conditions. These observations are supported by those of others who reported increased levels of iNOS mRNA and NO production in vitro and in vivo by mammalian cells, particularly macrophages, in the presence of IFN- and numerous pathogens including other parasitic protozoa such as the apicomplexans, Plasmodium falciparum, Babesia bovis, and Toxoplasma gondii, as well as trypanosomes such as Leishmania major and Trypanosoma cruzi (14, 20, 23, 27, 33, 34). In the case of EPM, however, these results do not indicate that the production of increased levels of NO is a mechanism of pathogenesis. Indeed, a slight inverse relationship between the levels of ataxia and the levels of NO_x^- in CSF appeared to occur. The results among the experimentally infected horses suggest that an increased level of NO production could have been associated with protection against S. neurona. However, it is noteworthy that both the naturally exposed and unexposed horses with neurologic disease had lower CSF NO_x^- levels than their neurologically normal counterparts. Thus, the association between a lack of clinical disease and higher levels of NO_x^- in CSF may not be due to the enhanced parasiticidal activity of NO and its metabolites per se, but, rather, the decreased levels of NO production could be associated with the onset of neurologic disease.

Another explanation for these observations is that higher NO levels in horses with subclinical disease suppress an immunopathogenic response to S. neurona, simultaneously reducing signs of ataxia and allowing the formation of parasitic lesions in the CNS. For example, NO production can affect the functional activity of interleukin-12 (IL-12), a cytokine that is required for priming of a type 1 helper T-cell response and IFN- production by NK and helper T cells (36). NO is required for transcription of the p40 subunit, but not the p35 subunit, of IL-12 in murine macrophages (28). However, high levels of NO production could result in the formation of p40 homodimers, which are antagonists of functionally active heterodimeric IL-12 (11). These observations are underscored by reports of increased steady-state levels of IL-12 p40 mRNA parallel to increased levels of iNOS mRNA in bovine macrophages stimulated in vitro with B. bovis in the presence of IFN- (33) and of augmented IFN- production, an indication of active heterodimeric IL-12, by antigen-stimulated spleen- or lung-associated lymph node cells from iNOS knockout mice infected with the protozoal parasite Trypanosoma brucei (15) or the trematode parasite Schistosoma mansoni (17). In addition, increased iNOS activity has been associated with suppression of the wild-type murine cellular immune response to T. brucei, as demonstrated by inhibition of spleen cell proliferation, which was partially reversed by an iNOS inhibitor (32). Thus, increased levels of NO production in response to S. neurona might result in a less pathogenic host immune response in the CNS, albeit one that is less protective against infection with the parasite. Further studies are required to elucidate the precise role of NO in immune protection and neuropathogenesis associated with EPM.

The association between CSF NO_x^- concentrations and ataxia are consistent with clinical observations by others who described ataxia and mild depression following exercise in experimental horses that were infused with the iNOS inhibitor N^G-L-nitro-arginine methyl ester (18, 24). Low levels of NO can lead to neurodegeneration through restricted cerebral blood flow (10, 35) and oxidative stress due to increased levels of superoxide production (38, 39). Reduction of the level of NO production can result from decreased levels of the NOS substrate L-arginine or a NOS coenzyme, tetrahydrobiotin (BH4) (37). Reduced levels of NO metabolites have been reported in association with several human neurologic diseases including cerebral malaria (2), Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple-system atrophy (19). Decreased levels of BH4 have also been associated with Alzheimer's and Parkinson's diseases (3, 25). The cause of the decreased CSF NO_x^- levels in horses with EPM appears to be either multifactorial (e.g., it can be caused by infection with S. neurona and stress) or a consequence of neurologic disease. These results suggest that theurapeutic objectives directed at increasing or maintaining NO levels in the CNS, such as treatment with dexamethasone, L-arginine, and/or BH4, could be effective therapy for EPM.

This work demonstrates a measurable difference between stressed and nonstressed horses in the onset of clinical EPM and indicates the importance of stress in the development of this disease under natural conditions. Further work is needed to determine the role of the parasitic infection in the reduction of CSF NO_x^- levels in horses with clinical EPM and to determine whether this observation is a cause or a consequence of the disease. Additionally, evaluation of the concentrations of NO_x^- in the CSF of C+ A+ horses that respond to antiprotozoal treatment could facilitate determination of the utility of this assay as a test for the presence of disease and the response to treatment.

The combination of a test that determines the CSF NO_x^- concentration and a test for Abs in CSF might increase the likelihood of a correct diagnosis and improve the prognosis with the advent of more effective treatments for EPM because an assay for determination of the concentration of CSF NO_x^- could be used to objectively distinguish between horses with clinical EPM and those only exposed to the parasite. However, a test for anti- S. neurona Abs in CSF would still be necessary because C- A+ horses could not be distinguished from those with EPM by determination of the CSF NO_x^- concentration alone. The presence of anti-S. neurona Abs and reduced levels of NO_x^- in horse sera could also be evaluated as a potential diagnostic test for EPM. A better "gold standard" for the diagnosis of EPM would be valuable in further determining the value of a test that measures the concentration of NO_x^- in CSF in identifying horses with this disease and in predicting the efficacies of different treatments. The utility of a more specific and/or sensitive test for Abs in CSF and the detection of Abs and NO_x^- in CSF among vaccinated horses that have not been exposed to S. neurona must also be determined.

 
This work was supported by American Live Stock Insurance (Geneva, Ill.), the Department of Veterinary Preventive Medicine at The Ohio State University, The Ohio State University College of Veterinary Medicine Equine Research Funds, and the Ohio Quarter Horse Association.

We are grateful to W. C. Brown for helpful comments during the preparation of the manuscript and thank D. L. Grover and J. Stanek for technical assistance.

 
* Corresponding author. Mailing address: Department of Veterinary Preventive Medicine, The Ohio State University, 1900 Coffey Rd., Columbus, OH 43210-1092. Phone: (614) 292-9702. Fax: (614) 292-4142. E-mail: stich.2{at}osu.edu.

Top Abstract Introduction Materials and Methods Results Discussion References

 

1
1. Adamson, D. C., B. Wildemann, M. Sasaki, J. D. Glass, J. C. McArthur, V. I. Christov, T. M. Dawson, and V. L. Dawson. 1996. Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41. Science 274:1917-1921.[Abstract/Free Full Text]
2
2. Anstey, N. M., J. B. Weinberg, M. Y. Hassanali, E. D. Mwaikambo, D. Manyenga, M. A. Misukonis, D. R. Arnelle, D. Hollis, M. I. McDonald, and D. L. Granger. 1996. Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J. Exp. Med. 184:557-567.[Abstract/Free Full Text]
3
3. Barford, P. A., J. A. Blair, C. Eggar, C. Hamon, C. Morar, and S. B. Whitburn. 1984. Tetrahydrobiopterin metabolism in the temporal lobe of patients dying with senile dementia of Alzheimer type. J. Neurol. Neurosurg. Psychiatry 47:736-738.[Abstract/Free Full Text]
4
4. Bentz, B. G., D. Granstrom, and S. Stamper. 1997. Seroprevalence of antibodies to Sarcocystis neurona in horses residing in a county of southeastern Pennsylvania. J. Am. Vet. Med. Assoc. 210:517-518.[Medline]
5
5. Blythe, L. L., D. E. Granstrom, D. E. Hansen, L. L. Walker, J. Bartlett, and S. Stamper. 1997. Seroprevalence of antibodies to Sarcocystis neurona in horses residing in Oregon. J. Am. Vet. Med. Assoc. 210:525-527.[Medline]
6
6. Cohen, N., and R. MacKay. 1997. Interpreting immunoblot testing of cerebrospinal fluid for equine protozoal myeloencephalitis. Compend. Contin. Educ. Pract. Vet. 19:1176-1181.
7
7. Dawson, V. L., and T. M. Dawson. 1996. Nitric oxide actions in neurochemistry. Neurochem. Int. 29:97-110.[CrossRef][Medline]
8
8. Dubey, J. P., S. W. Davis, C. A. Speer, D. D. Bowman, A. de Lahunta, D. E. Granstrom, M. J. Topper, A. N. Hamir, J. F. Cummings, and M. M. Suter. 1991. Sarcocystis neurona n. sp. (Protozoa: Apicomplexa), the etiologic agent of equine protozoal myeloencephalitis. J. Parasitol. 77:212-218.[CrossRef][Medline]
9
9. Dubey, J. P., D. S. Lindsay, W. J. Saville, S. M. Reed, D. E. Granstrom, and C. A. Speer. 2001. A review of Sarcocystis neurona and equine protozoal myeloencephalitis (EPM). Vet. Parasitol. 95:89-131.[CrossRef][Medline]
10
10. Gally, J. A., P. R. Montague, G. N. Reeke, Jr., and G. M. Edelman. 1990. The NO hypothesis: possible effects of a short-lived, rapidly diffusible signal in the development and function of the nervous system. Proc. Natl. Acad. Sci. USA 87:3547-3551.[Abstract/Free Full Text]
11
11. Gillessen, S., D. Carvajal, P. Ling, F. J. Podlaski, D. L. Stremlo, P. C. Familletti, U. Gubler, D. H. Presky, A. S. Stern, and M. K. Gately. 1995. Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur. J. Immunol. 25:200-206.[Medline]
12
12. Granstrom, D. E., and S. M. Reed. 1994. Equine protozoal myeloencephalitis. Equine Pract. 16:23-26.
13
13. Green, E. M., G. M. Constantinescu, and R. A. Kroll. 1992. Equine cerebrospinal fluid: physiologic principles and collection techniques. Comp. Cont. Educ. Pract. Vet. 14:229-237.
14
14. Green, S. J., R. M. Crawford, J. T. Hockmeyer, M. S. Meltzer, and C. A. Nacy. 1990. Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha. J. Immunol. 145:4290-4297.[Abstract]
15
15. Hertz, C. J., and J. M. Mansfield. 1999. IFN-gamma-dependent nitric oxide production is not linked to resistance in experimental African trypanosomiasis. Cell. Immunol. 192:24-32.[CrossRef][Medline]
16
16. Irazuzta, J. E., L. D. Mirkin, and B. Zingarelli. 2000. Mercaptoethylguanidine attenuates inflammation in bacterial meningitis in rabbits. Life Sci. 67:365-372.[CrossRef][Medline]
17
17. James, S. L., A. W. Cheever, P. Caspar, and T. A. Wynn. 1998. Inducible nitric oxide synthase-deficient mice develop enhanced type 1 cytokine-associated cellular and humoral immune responses after vaccination with attenuated Schistosoma mansoni cercariae but display partially reduced resistance. Infect. Immun. 66:3510-3518.[Abstract/Free Full Text]
18
18. Kindig, C. A., L. L. Gallatin, H. H. Erickson, M. R. Fedde, and D. C. Poole. 2000. Cardiorespiratory impact of the nitric oxide synthase inhibitor L-NAME in the exercising horse. Respir. Physiol. 120:151-166.[CrossRef][Medline]
19
19. Kuiper, M. A., J. J. Visser, P. L. Bergmans, P. Scheltens, and E. C. Wolters. 1994. Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients. J. Neurol. Sci. 121:46-49.[CrossRef][Medline]
20
20. Langermans, J. A., M. E. Van der Hulst, P. H. Nibbering, P. S. Hiemstra, L. Fransen, and R. Van Furth. 1992. IFN-gamma-induced L-arginine-dependent toxoplasmastatic activity in murine peritoneal macrophages is mediated by endogenous tumor necrosis factor-alpha. J. Immunol. 148:568-574.[Abstract]
21
21. MacKay, R. J. 1997. Equine protozoal myeloencephalitis. Vet. Clin. N. Am. Equine Pract. 13:79-96.[Medline]
22
22. MacKay, R. J., D. E. Granstrom, W. J. Saville, and S. M. Reed. 2000. Equine protozoal myeloencephalitis. Vet. Clin. N. Am. Equine Pract. 16:405-425.[Medline]
23
23. Metz, G., Y. Carlier, and B. Vray. 1993. Trypanosoma cruzi upregulates nitric oxide release by IFN-gamma-preactivated macrophages, limiting cell infection independently of the respiratory burst. Parasite Immunol. 15:693-699.[Medline]
24
24. Mills, P. C., D. J. Marlin, C. M. Scott, and N. C. Smith. 1997. Nitric oxide and thermoregulation during exercise in the horse. J. Appl. Physiol. 82:1035-1039.[Abstract/Free Full Text]
25
25. Nagatsu, T., T. Yamaguchi, T. Kato, T. Sugimoto, S. Matsuura, M. Akino, I. Nagatsu, R. Iizuka, and H. Narabayashi. 1981. Biopterin in human brain and urine from controls and Parkinsonian patients: application of a new radioimmunoassay. Clin. Chim. Acta 109:305-311.[CrossRef][Medline]
26
26. Navarro, J. A., J. A. Molina, F. J. Jimenez-Jimenez, J. Benito-Leon, M. Orti-Pareja, T. Gasalla, F. Cabrera-Valdivia, C. Vargas, F. de Bustos, and J. Arenas. 1996. Cerebrospinal fluid nitrate levels in patients with Alzheimer's disease. Acta Neurol. Scand. 94:411-414.[Medline]
27
27. Rockett, K. A., D. Kwiatkowski, C. A. Bate, M. M. Awburn, E. J. Rockett, and I. A. Clark. 1996. In vitro induction of nitric oxide by an extract of Plasmodium falciparum. J. Infect. 32:187-196.[CrossRef][Medline]
28
28. Rothe, H., B. Hartmann, P. Geerlings, and H. Kolb. 1996. Interleukin-12 gene-expression of macrophages is regulated by nitric oxide. Biochem. Biophys. Res. Commun. 224:159-163.[CrossRef][Medline]
29
29. Saville, W. J., S. M. Reed, D. E. Granstrom, K. W. Hinchcliff, C. W. Kohn, T. E. Wittum, and S. Stamper. 1997. Seroprevalence of serum antibodies to Sarcocystis neurona in horses residing in Ohio. J. Am. Vet. Med. Assoc. 210:519-524.[Medline]
30
30. Saville, W. J., S. M. Reed, P. S. Morley, D. E. Granstrom, C. W. Kohn, K. W. Hinchcliff, and T. E. Wittum. 2000. Analysis of risk factors for the development of equine protozoal myeloencephalitis in horses. J. Am. Vet. Med. Assoc. 217:1174-1180.[CrossRef][Medline]
31
31. Saville, W. J., R. W. Stich, S. M. Reed, C. J. Njoku, M. J. Oglesbee, A. Wunschmann, D. L. Grover, A. L. Larew-Naugle, J. F. Stanek, D. E. Granstrom, and J. P. Dubey. 2001. Utilization of stress in the development of an equine model for equine protozoal myeloencephalitis. Vet. Parasitol. 95:211-222.[CrossRef][Medline]
32
32. Schleifer, K. W., and J. M. Mansfield. 1993. Suppressor macrophages in African trypanosomiasis inhibit T cell proliferative responses by nitric oxide and prostaglandins. J. Immunol. 151:5492-5503.[Abstract]
33
33. Shoda, L. K., K. A. Kegerreis, C. E. Suarez, I. Roditi, R. S. Corral, G. M. Bertot, J. Norimine, and W. C. Brown. 2001. DNA from protozoan parasites Babesia bovis, Trypanosoma cruzi, and T. brucei is mitogenic for B lymphocytes and stimulates macrophage expression of interleukin-12, tumor necrosis factor alpha, and nitric oxide. Infect. Immun. 69:2162-2171.[Abstract/Free Full Text]
34
34. Stich, R. W., L. K. Shoda, M. Dreewes, B. Adler, T. W. Jungi, and W. C. Brown. 1998. Stimulation of nitric oxide production in macrophages by Babesia bovis. Infect. Immun. 66:4130-4136.[Abstract/Free Full Text]
35
35. Tanaka, K., F. Gotoh, S. Gomi, S. Takashima, B. Mihara, T. Shirai, S. Nogawa, and E. Nagata. 1991. Inhibition of nitric oxide synthesis induces a significant reduction in local cerebral blood flow in the rat. Neurosci. Lett. 127:129-132.[CrossRef][Medline]
36
36. Trinchieri, G., and P. Scott. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions. Res. Immunol. 146:423-431.[CrossRef][Medline]
37
37. Vasquez-Vivar, J., B. Kalyanaraman, P. Martasek, N. Hogg, B. S. Masters, H. Karoui, P. Tordo, and K. A. Pritchard, Jr. 1998. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. USA 95:9220-9225.[Abstract/Free Full Text]
38
38. Vidwans, A. S., S. Kim, D. O. Coffin, D. A. Wink, and S. J. Hewett. 1999. Analysis of the neuroprotective effects of various nitric oxide donor compounds in murine mixed cortical cell culture. J. Neurochem. 72:1843-1852.[CrossRef][Medline]
39
39. Wink, D. A., Y. Vodovotz, M. B. Grisham, W. DeGraff, J. C. Cook, R. Pacelli, M. Krishna, and J. B. Mitchell. 1999. Antioxidant effects of nitric oxide. Methods Enzymol. 301:413-424.[Medline]

---

Clinical and Diagnostic Laboratory Immunology, May 2002, p. 605-610, Vol. 9, No. 3
1071-412X/02/$04.00+0     DOI: 10.1128/CDLI.9.3.605-610.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Njoku, C. J. Articles by Stich, R. W. Search for Related Content PubMed PubMed Citation Articles by Njoku, C. J. Articles by Stich, R. W.